Multimodal cancer therapy involving oncolytic Newcastle Disease Virus, autologous immune cells and bispecific antibodies

Frontiers in Oncology

Volumn 4 AUG, Issue , 2014, Pages

  Schirrmacher, Volker ^a   Fournier, Philippe ^b  

^a Immunologisch Onkologisches Zentrum Koln IOZK   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Bispecific antibodies; Cellular therapy; Dendritic cells; Hyperthermia; Newcastle disease virus; T cells; Tumor targeting

Indexed keywords

BISPECIFIC ANTIBODY; VIRUS ANTIGEN; ONCOLYTIC VIRUS; RAC1 PROTEIN; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANTINEOPLASTIC ACTIVITY; CELL ACTIVATION; CELL THERAPY; DENDRITIC CELL; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOSTIMULATION; LIVER FIBROSIS; MULTIMODALITY CANCER THERAPY; NEWCASTLE DISEASE; NONHUMAN; REVIEW; T LYMPHOCYTE; TRANSGENE; VIROTHERAPY; VIRUS REPLICATION; ARTICLE; CARCINOGENESIS; IMMUNE RESPONSE; IMMUNOGENICITY; NEWCASTLE DISEASE PARAMYXOVIRUS; ONCOLYTIC VIROTHERAPY; TUMOR MICROENVIRONMENT;

EID: 84906223764     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00224     Document Type: Review

References (54)

1. Lech PJ, Russell SJ. Use of attenuated paramyxoviruses for cancer therapy. Expert Rev Vaccines (2010) 9(11):1275-302. doi: 10.1586/erv.10.124
2. Wilden H, Fournier P, Zawatzky R, Schirrmacher V. Expression of RIG-I, IRF3, IFN-ß and IRF7 determines resistance or susceptibility of cells to infection by Newcastle Disease Virus. Int J Oncol (2009) 34(4):971-82
3. Fournier P, Schirrmacher V. Oncolytic Newcastle Disease Virus as cutting edge between tumor and host (2013) Biology 2:1-41. Doi:10.3390/biology20x000x
4. Lazar I, Yaacov B, Shiloach T et al. The oncolytic activity of Newcastle disease virus NDVHUJ on chemoresistant primary melanoma cells is dependent on the proapoptotic activity of the inhibitor of apoptosis protein Livin. J Virol (2010) 84(1):639-46. Doi: 10.1128/JVI.00401-09
5. Mansour M, Palese P, Zamarin D. Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells. J Virol (2011) 85(12):6015-23. Doi: 10.1128/JVI.01537-10.
6. Meng S, Zhou Z, Chen F, et al. Newcastle disease virus induces apoptosis in cisplatinresistant human lung adenocarcinoma A549 cells in vitro and in vivo. Cancer Lett. (2012) 317(1):56-64. Doi: 10.1016/j.canlet.2011.11.008.
7. Chǹg WC, Stanbridge EJ, YusoffK, Shafee N, The oncolytic activity of Newcastle disease virus in clear cell renal carcinoma cells in normal and hypoxic conditions: the interplay between von Hippel-Lindau and interferon-ß signaling. J Interferon Cytokine Res. (2013) 33(7):346-54. Doi: 10.1089/jir.2012.0095.
8. Puhlmann J, Puehler F, Mumberg D, Boukamp P, Beier R. Rac1 is required for oncolytic NDV replication in human cancer cells and establishes a link between tumorigeneis and sensitivity to oncolytic virus. Oncogene (2010) 29:2205-16. Doi: 10.1038/onc.2009.507.
9. Meng C, Zhou Z, Jiang K et al, Newcastle disease virus triggers autophagy in U251 glioma cells to enhance virus replication. Arch Virol. (2012) 157(6):1011. Doi: 10.1007/s00705-012-1270-6.
10. Molouki A, Hsu YT, Jahanshiri F, Rosli R, YusoffK. Newcastle disease virus infection promotes Bax redistribution to mitochondria and cell death in HeLa cells. Intervirology (2010) 53(2):87-94. Doi: 10.1159/000264198.
11. Ravindra PV, Tiwari AK, Ratta B et al. Time course of Newcastle disease virus-induced apoptotic pathways. Virus Res (2009) 144:350-4. Doi: 10.1016/j.virusres.2009.05.012.
12. Li YL, Wu J, Wei D et al. Newcastle disease virus represses the activation of human hepatic stellate cells and reverses the development of hepatic fibrosis in mice. Liver Int. (2009) 29(4):593-602. Doi: 10.1111/j.1478-3231.2009.01971.x.
13. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest (2005) 115:209-18
14. Silberhumer GR, Brader P, Wong J et al. (2010) Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma. Mol Cancer Ther 9(10):2761-9. Doi: 10.1158/1535-7163.MCT-10-0090
15. Altomonte J, Marozin S, Schmid RM, Ebert O (2010) Engineered Newcastle disease virus as an improved oncolytic agent against hepatocellular carcinoma. Mol Ther 18(2):275-84. Doi: 10.1038/mt.2009.231.
16. Zamarin D, Martinez-Sobrido L, Kelly K et al. (2009) Enhancement of oncolytic properties of recombinant Newcastle disease virus through antagonism of cellular innate immune responses. Mol Ther 17(4):697-706. Doi: 10.1038/mt.2008.286.
17. Wu Y, Zhang X, Wang X et al. (2012) Apoptin enhances the oncolytic properties of Newcastle disease virus. Intervirology 55(4):276-86. Doi: 10.1159/000328325.
18. Janke M, Peeters B, Zhao H et al. (2008) Activation of human T cells by a tumor vaccine infected with recombinant Newcastle disease virus producing IL-2. Int J Oncol 33(4):823-32
19. Janke M, Peeters B, de Leeuw O et al. (2007) Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy. Gene Ther 14(23):1639-49.
20. Niu Z, Bai F, Sun T et al. (2014) Recombinant Newcastle Disease virus expressing IL-15 demonstrates promising antitumor efficiency in melanoma model. Technol Cancer Res Treat. Mar 17. PMID: 24645750
21. Susta L, Cornax I, Diel DG et al. (2013) Expression of interferon gamma by a highly virulent strain of Newcastle disease virus decreases its pathogenicity in chickens. Microb Pathog 61-62:73-83. doi: 10.1016/j.micpath.2013.05.009
22. Biswas M, Johnson JB, Kumar SR, Parks GD, Elankumarana S (2012) Incorporation of host complement regulatory protein into Newcastle disease virus enhances complement evasion. J Virol 86(23): 12708-16. doi: 10.1128/JVI.00886-12
23. Pühler F, Willuda J, Puhlmann J, Mumberg D, Römer-Oberdörfer A, Beier R (2008) Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes. Gene Ther 15(5):371-83. doi: 10.1038/sj.gt.3303095
24. Shobana R, Samal SK, Elankumaran S (2013) Prostate-specific antigen-retargeted recombinant Newcastle disease virus for prostate cancer virotherapy. J Virol 87(7):3792-800. doi: 10.1128/JVI.02394-12
25. Bach P et al. (2013) Specific elimination of CD133+ tumor cells with targeted oncolytic measles virus. Cancer Res 15:865-74
26. Aigner M, Janke M, Lulei M et al. (2008) An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins. Int J Oncol 32(4):777-89
27. Fournier P, Aigner M, Schirrmacher V (2010) Optimization studies for the coupling of bispecific antibodies to viral anchor molecules of a tumor vaccine. Int J Oncol 37(5):1203-17
28. Fournier P, Aigner M, Schirrmacher V (2010) Transcriptome analysis and cytokine profiling of naïve T cells stimulated by a tumor vaccine via CD3 and CD25. Int J Oncol 37(6):1439-52
29. Fournier P, Schirrmacher V (2013) Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future. BioDrugs 27(1):35-53. doi: 10.1007/s40259-012-0008-z
30. Lorence RM et al (1994) Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy. J Natl Cancer Inst 86:1228-33
31. Zamarin D, Holmgaard RB, Subudhi S et al. (2014) Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Science Translational Med 6(226): 1-12
32. Apostolidis L, Schirrmacher V, Fournier P (2007) Host mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional application. Int J Oncol 31(5): 1009-19
33. Csatary LK et al. (1993) Attenuated veterinary virus vaccine for the treatment of cancer. Cancer Detect Prev 17:619-27
34. Song KY, Wong J, Gonzales L, Sheng G, Zamarin D, Fong Y (2010) Antitumor efficacy of viral therapy using genetically engineered Newcastle disease virus [NDV(F3aa)-GFP] for peritoneally disseminated gastric cancer. J Mol Med (Berl). 88(6):589-96. doi: 10.1007/s00109-010-0605-6
35. Demers GW, Johnson DE, Tsai V et al. (2003) Pharmacologic indicators of antitumor efficacy of oncolytic virotherapy. Cancer Res 63:4003-8
36. Bian H, Fournier P, Moormann R, Peeters B, Schirrmacher V (2005) Selective gene transfer in vitro to tumor cells via recombinant Newcastle disease virus. Cancer Gene Ther 12:295-303
37. Bian H, Fournier P, Moormann R, Peeters B, Schirrmacher V (2005) Selective gene transfer to tumor cells by recombinant Newcastle disease virus via a bispecific fusion protein. Int J Oncol 26:431-439
38. Bian H, Wilden H, Fournier P, Peeters B, Schirrmacher V (2006) In vivo efficacy of systemic tumor targeting of a viral RNA vector with oncolytic properties using a bispecific adapter protein. Int J Oncol 29(6):1359-69
39. Schirrmacher V, Haas C, Bonifer R, Ahlert T, Gerhards R, Ertel C (1999) Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. Gene Ther 6(1):63-73
40. Schulze T, Kemmner W, Weitz J, Wernecke KD, Schirrmacher V, Schlag PM (2009) Efficiency of adjuvant active-specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial. Cancer Immunol Immunother 58(1):61-9
41. Haas C, Lulei M, Fournier P, Arnold A, Schirrmacher V (2006) A tumor vaccine containing anti-CD3 and anti-CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes. Int J Cancer 118(3):658-67
42. Fournier P, Schirrmacher V (2010) Tumor antigen-dependent and tumor antigenindependent activation of antitumor activity in T cells by a bispecific antibody-modified vaccine. Clin Dev Immunol 2010:423781. doi: 10.1155/2010/423781
43. Aigner M, Janke M, Lulei M, Beckhove P, Fournier P, Schirrmacher V (2008) An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins. Int J Oncol 32(4):777-89
44. Fournier P, Arnold A, Schirrmacher V (2009) Polarization of human monocyte-derived dendritic cells to DC1 by in vitro stimulation with Newcastle Disease Virus. J BUON 2009;14 Suppl 1:S111-22
45. Fournier P, Arnold A, Wilden H, Schirrmacher V (2012) Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity. Int J Oncol 40(3):840-50
46. Hornung V et al. (2006) Triphosphate RNA is the ligand for RIG-1. Science 314:994-7
47. Poeck H et al. (2010) Recognition of RNA virus by RIG-1 results in activation of CARD9 and inflammasome signaling for interfeulin 1 beta production. Nat Immunol 11:63-9
48. Xiao Z, Casey KA, Jameson SC, Curtsinger JM, Mescher MF (2009) Programming for CD8 T cell memory development requires IL-12 or type I IFN. J Immunol 182:2786-94
49. Santarlasci V, Cosmi L, Maggi L, Liotta F, Annunziato F (2013) IL-1 and T helper immune responses. Front Immunol 4:182. doi: 10.3389/fimmu.2013.00182
50. Bai L, Koopmann J, Fiola C, Fournier P, Schirrmacher V (2002) Dendritic cells pulsed with viral oncolysate potently stimulate autologous T cells from cancer Patients. Int J Oncol 21(4):685-94
51. Klug F, Prakash H, Huber PE et al. (2013) Low-dose irradiation programs macrophage differentiation to an iNOS+/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell 24(5):589-602. doi: 10.1016/j.ccr.2013.09.014
52. Knippertz I, Stein MF, Dörrie J et al. (2011) Mild hyperthermia enhances human monocytederived dendritic cell functions and offers potential for applications in vaccination strategies. Int J Hyperthermia 27(6):591-603
53. Schirrmacher V, Bihar AS, Stuecker W, Sprenger T (2014) Long-term remission of prostate cancer with extensive bone metastases upon immune- and virotherapy: A case report. Cancer letters, in press
54. Pfirschke C, Schirrmacher V (2009) Cross-infection of tumor cells by contact with T lymphocytes loaded with Newcastle disease virus. Int J Oncol 34:951-62